Amsterdam UMC, location AMC
Amsterdam, 1105AZ, Netherlands
Location status: Recruiting
Location contact
Anna van Veelen, MD
CONTACT
NCT Number: NCT03756870
Rationale: Randomized trials could not yet establish favourable outcomes of CTO PCI on hard endpoints such as ejection fraction or mortality, when compared to optimal medical therapy. However, patients after CTO PCI appeared to be more frequently free of angina complaints, but the aetiology behind this is not fully understood. The investigators hypothesize that PCI of the CTO in patients preselected with an ischemic threshold (>12.5%) on cardiac imaging leads to a reduction of the ischemic burden and therefore an increased benefit on functional outcomes.
Objective: Primary objective is to determine whether PCI of the CTO will yield a higher reduction of ischemia assessed by exercise myocardial perfusion SPECT-CT from baseline to 6-month follow-up compared to a control group. Secondary objectives are 1) to evaluate the effect of PCI of the CTO on improvement in functional status, infarct size and left ventricular function from baseline to follow-up compared to the control group; 2) to study the association between ischemia reduction and functional outcome and left ventricular function; 3) to assess the influence of the collateral flow index on the ischemic burden (reduction), functional status, infarct size and left ventricular (contractile) function (hibernation).
Study design: open multicentre randomized trial
Study population: 2x24 patients eligible for CTO PCI
Intervention: CTO PCI
Primary endpoint: ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Amsterdam, 1105AZ, Netherlands
Location status: Recruiting
Anna van Veelen, MD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The ischemic threshold is defined as:
Exclusion criteria
A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
Time frame: 6 months follow-up
Ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.
Time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years
5 Seattle Angina Questionnaire subscales (0-100), higher scores indicating better angina status.
Time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years
MLHFQ scale (0-105), lower scores indicating better quality of life.
Time frame: 6 months
Contact information is provided by the study sponsor or research team.
Ms. A. van Veelen, MD
CONTACT
Prof. J.P.S. Henriques, MD PhD
CONTACT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
REvascularization Versus Optimal Medical Therapy on Left Ventricular ISchemia Reduction: Exploring the Associations Between Ischemia, Functional Outcome and Collaterals in the Treatment of Chronic Total Occlusion Patients
Acronym: REVISE-CTO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03563417
Cardiovascular Diseases, Chronic Total Occlusion of Coronary Artery
Aarhus N, Denmark
View Trial DetailsNCT06358508
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial DetailsNCT01106534
Arterial Occlusive Diseases, Arteriosclerosis
Birmingham, Alabama, United States
View Trial DetailsNCT03988166
Cardiovascular Diseases, Chronic Total Occlusion
Torrance, California, United States
View Trial Details